Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131-I chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

		Phase:		Phase 1

		Treatment ID#:		1774 PPHM 0602

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Prior Surgery is Sometimes Allowed Prior Radiation is Sometimes Allowed Prior Chemotherapy is Sometimes Allowed Glioblastoma Multiforme

		Last Updated:		07/31/2007

		Tumor Types:		Glioblastoma Multiforme


		Comments:		An interval of at least 3 months must have elapsed since the completion of the most recent course of radiation therapy while at least 4 weeks must have elapsed since the completion of a non-nitrosourea containing chemotherapy regimen and at least 6 weeks since the completion of a nitrosourea containing chemotherapy regimen. An interval of at least 4 weeks must have elapsed from time of surgery. Patients who have had Gliadel are eligible however; an interval of at least 3 months must have elapsed since the Gliadel wafers have been implanted.

		Treatment Type:		Immunological, Biological or Targeted Therapy

		Contact:		Jennifer Spallone Clinical Research Associate Peregrine Pharmaceuticals 14272 Franklin Ave. Tustin, CA 92780 USA Phone: 714-508-6097 Fax: E-mail: jspallone@peregrineinc.com Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By